Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1984 1
1989 4
1990 4
1992 1
1993 2
1995 1
1996 6
1997 1
2001 1
2002 7
2003 6
2004 7
2005 9
2006 5
2007 9
2008 4
2009 4
2010 1
2011 1
2012 2
2013 4
2014 2
2015 2
2016 5
2017 4
2018 4
2019 6
2020 8
2021 18
2022 9
2023 10
2024 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Eikelboom JW, et al. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844192 Free article. Clinical Trial.
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Nakachi K, et al. Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4. Lancet. 2023. PMID: 36681415 Clinical Trial.
TOKYO criteria 2024 for the assessment of clinical outcomes of endoscopic biliary drainage.
Isayama H, Hamada T, Fujisawa T, Fukasawa M, Hara K, Irisawa A, Ishii S, Ito K, Itoi T, Kanno Y, Katanuma A, Kato H, Kawakami H, Kawamoto H, Kitano M, Kogure H, Matsubara S, Mukai T, Naitoh I, Ogura T, Ryozawa S, Sasaki T, Shimatani M, Shiomi H, Sugimori K, Takenaka M, Yasuda I, Nakai Y, Fujita N, Inui K; Research Group of Evaluation Criteria for Endoscopic Biliary Drainage. Isayama H, et al. Among authors: sugimori k. Dig Endosc. 2024 Nov;36(11):1195-1210. doi: 10.1111/den.14825. Epub 2024 Jun 6. Dig Endosc. 2024. PMID: 38845085 Review.
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Morizane C, et al. Among authors: sugimori k. Ann Oncol. 2019 Dec 1;30(12):1950-1958. doi: 10.1093/annonc/mdz402. Ann Oncol. 2019. PMID: 31566666 Free article. Clinical Trial.
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Ueno H, et al. Among authors: sugimori k. J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1. J Clin Oncol. 2013. PMID: 23547081 Clinical Trial.
New image-enhanced cholangioscopy for the diagnosis of cholangiocarcinoma.
Ishii T, Kaneko T, Murakami A, Ueda M, Sugimori K, Kawana I, Maeda S. Ishii T, et al. Among authors: sugimori k. Endoscopy. 2023 Dec;55(S 01):E139-E140. doi: 10.1055/a-1956-0967. Epub 2022 Oct 28. Endoscopy. 2023. PMID: 36307073 Free PMC article. No abstract available.
Development of a nomogram to predict survival in advanced biliary tract cancer.
Imaoka H, Ikeda M, Nomura S, Morizane C, Okusaka T, Ozaka M, Shimizu S, Yamazaki K, Okano N, Sugimori K, Shirakawa H, Mizuno N, Satoi S, Yamaguchi H, Sugimoto R, Gotoh K, Sano K, Asagi A, Nakamura K, Ueno M. Imaoka H, et al. Among authors: sugimori k. Sci Rep. 2023 Dec 6;13(1):21548. doi: 10.1038/s41598-023-48889-6. Sci Rep. 2023. PMID: 38057434 Free PMC article.
A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy.
Furuse J, Ikeda M, Ueno M, Furukawa M, Morizane C, Takehara T, Nishina T, Todaka A, Okano N, Hara K, Nakai Y, Ohkawa K, Sasaki T, Sugimori K, Yokoyama N, Yamamoto K. Furuse J, et al. Among authors: sugimori k. Clin Cancer Res. 2024 Sep 13;30(18):3990-3995. doi: 10.1158/1078-0432.CCR-24-0461. Clin Cancer Res. 2024. PMID: 39058429 Clinical Trial.
148 results